Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis

References

• Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin. 2005;23:17–38.
   PubMed Web of Science ®Google Scholar
• Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ Br Med J. 2006;332:525–527.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133:1914–1929.
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007 Apr;61(4):300-306.
   Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med. 2006;354:942–955.
   PubMed Web of Science ®Google Scholar
• Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007;184:37–44.
   PubMed Web of Science ®Google Scholar
• Franklin RJM, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9:839–855.
   PubMed Web of Science ®Google Scholar
• Charcot JM. Lectures on the disease of the nervous system. New Sydenham Soc. 1877;XC.
   Google Scholar
• Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb Clin Neurol. 2014;122:15–58.
   PubMedGoogle Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–1189.
   PubMed Web of Science ®Google Scholar
• Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126:433–437.
   PubMed Web of Science ®Google Scholar
• Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225–238.
   PubMed Web of Science ®Google Scholar
• Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry. 1992;55:450–453.
   PubMed Web of Science ®Google Scholar
• Gallo P, Chiusole M, Sanzari M, et al. Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients. Acta Neurol Scand. 1994;89:95–101.
   PubMed Web of Science ®Google Scholar
• Goodkin DE. Interferon β therapy for multiple sclerosis. Lancet. 1998;352:1486–1487.
   PubMed Web of Science ®Google Scholar
• Hohlfeld R, Kerschensteiner M, Stadelmann C, et al. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci. 2006;27(Suppl 1):S1–S7.
   PubMed Web of Science ®Google Scholar
• Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci. 2013;328(1–2):9–18.
   PubMed Web of Science ®Google Scholar
• Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci. 2002;3(9):705–714.
   PubMed Web of Science ®Google Scholar
• Chang A, Tourtellotte WW, Rudick R, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002;346:165–173.
   PubMed Web of Science ®Google Scholar
• Harlow DE, Honce JM, Miravalle AA. Remyelination therapy in multiple sclerosis. Front Neurol. 2015;6(DEC):1–13.
   PubMed Web of Science ®Google Scholar
• Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745–751.
   PubMed Web of Science ®Google Scholar
• Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13(10):1228–1233.
   PubMed Web of Science ®Google Scholar
• Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci. 2004;7(3):221–228.
   PubMed Web of Science ®Google Scholar
• Ji B, Li M, Wu W-T, et al. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci. 2006;33:311–320.
   PubMed Web of Science ®Google Scholar
• Llorens F, Gil V, Iraola S, et al. Developmental analysis of Lingo-1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l. Dev Neurobiol. 2008;68:521–541.
   PubMed Web of Science ®Google Scholar
• Song H, Poo M. The cell biology of neuronal navigation. Nat Cell Biol. 2001;3:E81–E88.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Mi S, Sandrock AW Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther. 2008;8:1561–1570.
   PubMed Web of Science ®Google Scholar
• Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003;4:703–713.
   PubMed Web of Science ®Google Scholar
• McGee AW, Strittmatter SM. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci. 2003;26:193–198.
   PubMed Web of Science ®Google Scholar
• Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65(3):304–315.
   PubMed Web of Science ®Google Scholar
• Pepinsky RB, Arndt JW, Quan C, et al. Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J Pharmacol Exp Ther. 2014;350(1):110–123.
   PubMed Web of Science ®Google Scholar
• Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27(7):493–503.
   PubMed Web of Science ®Google Scholar
• Pepinsky RB, Shao Z, Ji B, et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J Pharmacol Exp Ther. 2011;339(2):519–529.
   PubMed Web of Science ®Google Scholar
• Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflammation. 2014;1(2):e18–e18.
   PubMedGoogle Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–199.
   PubMed Web of Science ®Google Scholar
• Cadavid D, Edwards KR, Hupperts R, et al.; On behalf of the S investigators. Efficacy analysis of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial. Mult Scler J. 2016;22(S3):7.
   PubMed Web of Science ®Google Scholar
• McCroskery P, Selmaj K, Fernandez O, et al.; On behalf of the S investigators. Safety and tolerability of opicinumab in relapsing multiple sclerosis: the phase 2b SYNERGY trial. Neurology. 2017;88. No. 16 Supplement P5.369.
   Google Scholar
• Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–1731.
   PubMed Web of Science ®Google Scholar
• Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13(sup2):3–9.
   PubMed Web of Science ®Google Scholar
• Aktas O, Albrecht P, Hartung H-P. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis. Curr Opin Neurol. 2016;29(3):199–204.
   PubMed Web of Science ®Google Scholar
• Rocca MA, Battaglini M, Benedict RHB, et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology. 2017;88(4):403–413.
   PubMed Web of Science ®Google Scholar
• Mallik S, Samson RS, Wheeler-Kingshott CAM, et al. Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1396–1404.
   PubMed Web of Science ®Google Scholar
• Bodini B, Veronese M, García-Lorenzo D, et al. Dynamic imaging of individual remyelination profiles in multiple sclerosis. Ann Neurol. 2016;79(5):726–738.
   PubMed Web of Science ®Google Scholar